Top

Published in:

01-12-2010 | Original Communication

The new Alzheimer’s criteria in a naturalistic series of patients with mild cognitive impairment

Authors: S. Galluzzi, C. Geroldi, R. Ghidoni, B. Paghera, G. Amicucci, M. Bonetti, O. Zanetti, M. Cotelli, M. Gennarelli, G. B. Frisoni, Translational Outpatient Memory Clinic Working Group

Published in: Journal of Neurology | Issue 12/2010

Abstract

To test the validity of the new diagnostic criteria for Alzheimer’s disease (AD) in a naturalistic series of patients with mild cognitive impairment (MCI). Ninety consecutive MCI patients were enrolled in a longitudinal study on the natural history of cognitive impairment. Medial temporal (MT) atrophy on MRI was defined as hippocampal volume below the fifth percentile of the distribution in healthy elders, abnormal CSF was based on Sjogren’s cutoffs for Abeta42 and tau, and temporoparietal hypometabolism on 18F-FDG PET based on Herholz’s t sum score. Patients were followed clinically to detect conversion to AD (MCI-AD), non-AD dementia (MCI-nAD), or no conversion (MCI-NC). The 24 MCI-AD and 15 MCI-nAD patients had sociodemographic, clinical, and neuropsychological baseline features similar to the 51 MCI-NC patients. All MCI patients with MT atrophy converted to AD, as did all those with abnormal CSF, but only 48 and 35% of those without MT atrophy or abnormal CSF converted (p on logrank test = 0.0007 and 0.001). Prediction of AD conversion was enhanced when positivity to either MT atrophy or abnormal CSF was considered, with only 15% of those MCI patients negative on both converting to AD (p < 0.0005). Markers were not predictive of non-AD dementia conversion. The accuracy of either MT atrophy or abnormal CSF in discriminating MCI-AD from MCI-NC was good (AUC 0.82, 95% CI 0.70–0.95). MT atrophy and abnormal CSF are the single most robust predictors of conversion to AD in MCI patients, and their combination enhances prediction. AD markers are not predictive of conversion to non-AD dementia.

Available only for authorised users

American Psychiatric Association (1994) Diagnostic and statistical manual of mental disorders, 4th edn. American Psychiatric Association, USA

Barabash A, Marcos A, Ancín I, Vázquez-Alvarez B, de Ugarte C, Gil P, Fernández C, Encinas M, López-Ibor JJ, Cabranes JA (2009) APOE, ACT and CHRNA7 genes in the conversion from amnestic mild cognitive impairment to Alzheimer’s disease. Neurobiol Aging 30:1254–1264CrossRefPubMed

Barber R, Ballard C, McKeith IG, Gholkar A, O’Brien JT (2000) MRI volumetric study of dementia with Lewy bodies: a comparison with AD and vascular dementia. Neurology 54:1304–1309PubMed

Bennett DA, Wilson RS, Schneider JA, Evans DA, Beckett LA, Aggarwal NT, Barnes LL, Fox JH, Bach J (2002) Natural history of mild cognitive impairment in older persons. Neurology 59:198–205PubMed

Bibl M, Mollenhauer B, Esselmann H, Lewczuk P, Trenkwalder C, Brechlin P, Rüther E, Kornhuber J, Otto M, Wiltfang (2006) CSF diagnosis of Alzheimer’s disease and dementia with Lewy bodies. J Neural Transm 113:1771–1778CrossRefPubMed

Blennow K, Hampel H (2003) CSF markers for incipient Alzheimer’s disease. Lancet Neurol 2:605–613CrossRefPubMed

Bresciani L, Rossi R, Testa C, Geroldi C, Galluzzi S, Laakso MP, Beltramello A, Soininen H, Frisoni GB (2005) Visual assessment of medial temporal atrophy on MR films in Alzheimer’s disease: comparison with volumetry. Aging Clin Exp Res 17:8–13PubMed

Brys M, Glodzik L, Mosconi L, Switalski R, De Santi S, Pirraglia E, Rich K, Kim BC, Mehta P, Zinkowski R, Pratico D, Wallin A, Zetterberg H, Tsui WH, Rusinek H, Blennow K, de Leon MJ (2009) Magnetic resonance imaging improves cerebrospinal fluid biomarkers in the early detection of Alzheimer’s disease. J Alzheimers Dis 16:351–362PubMed

Craig-Schapiro R, Fagan AM, Holtzman DM (2009) Biomarkers of Alzheimer’s disease. Neurobiol Dis 35:128–140CrossRefPubMed

10.

De Leo D, Frisoni GB, Rozzini R, Trabucchi M (1993) Italian community norms for the Brief Symptom Inventory in the elderly. Br J Clin Psychol 32:209–213PubMed

11.

Devanand DP, Pradhaban G, Liu X, Khandji A, De Santi S, Segal S, Rusinek H, Pelton GH, Honig LS, Mayeux R, Stern Y, Tabert MH, de Leon MJ (2007) Hippocampal and entorhinal atrophy in mild cognitive impairment: prediction of Alzheimer disease. Neurology 68:828–836CrossRefPubMed

12.

Devanand DP, Pelton GH, Zamora D, Liu X, Tabert MH, Goodkind M, Scarmeas N, Braun I, Stern Y, Mayeux R (2005) Predictive utility of apolipoprotein E genotype for Alzheimer disease in outpatients with mild cognitive impairment. Arch Neurol 62:975–980CrossRefPubMed

13.

Devous MD Sr (2002) Functional brain imaging in the dementias: role in early detection, differential diagnosis, and longitudinal studies. Eur J Nucl Med Mol Imaging 29:1685–1696CrossRefPubMed

14.

Drzezga A, Grimmer T, Riemenschneider M, Lautenschlager N, Siebner H, Alexopoulus P, Minoshima S, Schwaiger M, Kurz A (2005) Prediction of individual clinical outcome in MCI by means of genetic assessment and (18)F-FDG PET. J Nucl Med 46:1625–1632PubMed

15.

Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, Cummings J, Delacourte A, Galasko D, Gauthier S, Jicha G, Meguro K, O’brien J, Pasquier F, Robert P, Rossor M, Salloway S, Stern Y, Visser PJ, Scheltens P (2007) Research criteria for the diagnosis of Alzheimer’s disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 6:734–746CrossRefPubMed

16.

Folstein MF, Folstein SE, McHugh PR (1975) Mini-Mental State: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189–198CrossRefPubMed

17.

Frisoni GB, Pievani M, Testa C, Sabattoli F, Bresciani L, Bonetti M, Beltramello A, Hayashi KM, Toga AW, Thompson PM (2007) The topography of grey matter involvement in early and late onset Alzheimer’s disease. Brain 130:720–730CrossRefPubMed

18.

Frisoni GB, Prestia A, Zanetti O, Galluzzi S, Romano M, Cotelli M, Gennarelli M, Binetti G, Bocchio L, Paghera B, Amicucci G, Bonetti M, Benussi L, Ghidoni R, Geroldi C (2009) Markers of Alzheimer’s disease in a population attending a memory clinic. Alzheimers Dement 5:307–317CrossRefPubMed

19.

Frisoni GB, Fox NC, Jack CR Jr, Scheltens P, Thompson PM (2010) The clinical use of structural MRI in Alzheimer’s disease. Nat Rev Neurol 6:67–77

20.

Galluzzi S, Testa C, Boccardi M, Bresciani L, Benussi L, Ghidoni R, Beltramello A, Bonetti M, Bono G, Falini A, Magnani G, Minonzio G, Piovan E, Binetti G, Frisoni GB (2009) The Italian Brain Normative Archive of structural MR scans: norms for medial temporal atrophy and white matter lesions. Aging Clin Exp Res 21:266–276PubMed

21.

Geuze E, Vermetten E, Bremner JD (2005) MR-based in vivo hippocampal volumetrics: 1 Review of methodologies currently employed. Mol Psychiatry 10:147–159CrossRefPubMed

22.

Gilman S, Koeppe RA, Little R et al (2005) Differentiation of Alzheimer’s disease from dementia with Lewy bodies utilizing positron emission tomography with [18F]fluorodeoxyglucose and neuropsychological testing. Exp Neurol 191:S95–S103CrossRefPubMed

23.

Hampel H, Bürger K, Teipel SJ, Bokde AL, Zetterberg H, Blennow K (2008) Core candidate neurochemical and imaging biomarkers of Alzheimer’s disease. Alzheimers Dement 4:38–48CrossRefPubMed

24.

Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L (2006) Association between CSF biomarkers and incipient Alzheimer’s disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 5:228–234CrossRefPubMed

25.

Herholz K, Salmon E, Perani D, Baron JC, Holthoff V, Frölich L, Schönknecht P, Ito K, Mielke R, Kalbe E, Zündorf G, Delbeuck X, Pelati O, Anchisi D, Fazio F, Kerrouche N, Desgranges B, Eustache F, Beuthien-Baumann B, Menzel C, Schröder J, Kato T, Arahata Y, Henze M, Heiss WD (2002) Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET. Neuroimage 17:302–316CrossRefPubMed

26.

Herholz K, Carter SF, Jones M (2007) Positron emission tomography imaging in dementia. Br J Radiol 80:S160–S167CrossRefPubMed

27.

Hixson JE, Vernier DT (1990) Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res 31:545–548PubMed

28.

Jack CR Jr, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, Petersen RC, Trojanowski JQ (2010) Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade. Lancet Neurol 9:119–128CrossRefPubMed

29.

Lawton MP, Brody EM (1969) Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 9:179–186PubMed

30.

Lezak M, Howieson D, Loring DW (2004) Neuropsychological assessment, 4th edn. University Press, Oxford

31.

Likeman M, Anderson VM, Stevens JM, Waldman AD, Godbolt AK, Frost C, Rossor MN, Fox NC (2005) Visual assessment of atrophy on magnetic resonance imaging in the diagnosis of pathologically confirmed young-onset dementias. Arch Neurol 62:1410–1415CrossRefPubMed

32.

Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M, Herukka SK, van der Flier WM, Blankenstein MA, Ewers M, Rich K, Kaiser E, Verbeek M, Tsolaki M, Mulugeta E, Rosén E, Aarsland D, Visser PJ, Schröder J, Marcusson J, de Leon M, Hampel H, Scheltens P, Pirttilä T, Wallin A, Jönhagen ME, Minthon L, Winblad B, Blennow K (2009) CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 302:385–393CrossRefPubMed

33.

McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, Salmon DP, Lowe J, Mirra SS, Byrne EJ, Lennox G, Quinn NP, Edwardson JA, Ince PG, Bergeron C, Burns A, Miller BL, Lovestone S, Collerton D, Jansen EN, Ballard C, de Vos RA, Wilcock GK, Jellinger KA, Perry RH (1996) Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 47:1113–1124PubMed

34.

McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 34:939–944PubMed

35.

McKhann GM, Albert MS, Grossman M, Miller B, Dickson D, Trojanowski JQ (2001) Work Group on Frontotemporal Dementia and Pick’s Disease Clinical and pathological diagnosis of frontotemporal dementia: report of the Work Group on Frontotemporal Dementia and Pick’s Disease. Arch Neurol 58:1803–1809

36.

Mosconi L, Perani D, Sorbi S, Herholz K, Nacmias B, Holthoff V, Salmon E, Baron JC, De Cristofaro MT, Padovani A, Borroni B, Franceschi M, Bracco L, Pupi (2004) MCI conversion to dementia and the APOE genotype: a prediction study with FDG-PET. Neurology 63:2332–2340PubMed

37.

Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E (1999) Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 56:303–308CrossRefPubMed

38.

Riemenschneider M, Wagenpfeil S, Diehl J, Lautenschlager N, Theml T, Heldmann B, Drzezga A, Jahn T, Förstl H, Kurz A (2002) Tau and Abeta42 protein in CSF of patients with frontotemporal degeneration. Neurology 58:1622–1628PubMed

39.

Risacher SL, Saykin AJ, West JD, Shen L, Firpi HA, McDonald BC, Alzheimer’s Disease Neuroimaging Initiative (ADNI) (2009) Baseline MRI predictors of conversion from MCI to probable AD in the ADNI cohort. Curr Alzheimer Res 6:347–361CrossRefPubMed

40.

Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, Blennow K, Soares H, Simon A, Lewczuk P, Dean R, Siemers E, Potter W, Lee VM, Trojanowski JQ, Alzheimer’s Disease Neuroimaging Initiative (2009) Cerebrospinal fluid biomarker signature in Alzheimer’s disease neuroimaging initiative subjects. Ann Neurol 65:403–413CrossRefPubMed

41.

Sjogren M, Vanderstichele H, Agren H, Zachrisson O, Edsbagge M, Wikkelsø C, Skoog I, Wallin A, Wahlund LO, Marcusson J, Nägga K, Andreasen N, Davidsson P, Vanmechelen E, Blennow K (2001) Tau and Abeta42 in cerebrospinal fluid from healthy adults 21–93 years of age: establishment of reference values. Clin Chem 47:1776–1781PubMed

42.

Vemuri P, Wiste HJ, Weigand SD, Shaw LM, Trojanowski JQ, Weiner MW, Knopman DS, Petersen RC, Jack CR Jr, Alzheimer’s Disease Neuroimaging Initiative (2009) MRI and CSF biomarkers in normal, MCI, and AD subjects: predicting future clinical change. Neurology 73:294–301CrossRefPubMed

43.

Verwey NA, van der Flier WM, Blennow K, Clark C, Sokolow S, De Deyn PP, Galasko D, Hampel H, Hartmann T, Kapaki E, Lannfelt L, Mehta PD, Parnetti L, Petzold A, Pirttila T, Saleh L, Skinningsrud A, Swieten JC, Verbeek MM, Wiltfang J, Younkin S, Scheltens P, Blankenstein MA (2009) A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer’s disease. Ann Clin Biochem 46:235–240CrossRefPubMed

44.

Wahlund LO, Barkhof F, Fazekas F, Bronge L, Augustin M, Sjögren M, Wallin A, Ader H, Leys D, Pantoni L, Pasquier F, Erkinjuntti T, Scheltens P, European Task Force on Age-Related White Matter Changes (2001) A new rating scale for age-related white matter changes applicable to MRI and CT. Stroke 32:1318–1322PubMed

Title: The new Alzheimer’s criteria in a naturalistic series of patients with mild cognitive impairment
Authors: S. Galluzzi
C. Geroldi
R. Ghidoni
B. Paghera
G. Amicucci
M. Bonetti
O. Zanetti
M. Cotelli
M. Gennarelli
G. B. Frisoni
Translational Outpatient Memory Clinic Working Group
Publication date: 01-12-2010
Publisher: Springer-Verlag
Published in: Journal of Neurology / Issue 12/2010
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI: https://doi.org/10.1007/s00415-010-5650-0

At a glance: The STEP trials

Springer Medicine

The new Alzheimer’s criteria in a naturalistic series of patients with mild cognitive impairment

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 12/2010

Korbinian Brodmann (1868–1918)

Primary cerebral lymphomatoid granulomatosis as an immune reconstitution inflammatory syndrome in AIDS

Late-onset Leber hereditary optic neuropathy mimicking Susac’s syndrome

Neuromuscular disorders and 2010: recent advances

Cerebral amyloid angiopathy related vasculitis: successful treatment with azathioprine

Communications of the European Neurological Society